ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Impact of hyperglycemia on glioblastoma cell proliferation and the therapeutic potential of green-synthesized cerium oxide nanoparticles.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetes mellitus (DM) is a major metabolic disorder that promotes cancer progression, including in glioblastoma cells. Persistent hyperglycemia alters the tumor microenvironment, increasing cell proliferation and disturbing oxidative balance. However, the molecular mechanisms connecting high-glucose levels to glioblastoma growth are not fully understood, and the role of redox-active nanomaterials in regulating this effect has not been thoroughly investigated. Therefore, this study investigated the effects of normoglycemic (i.e., at 5 mM) and hyperglycemic (i.e., at 10 and 25 mM) conditions on U87 glioblastoma cells at 24, 48, and 72 h, followed by treatment with Mentha-derived green-synthesized cerium oxide nanoparticles (CeO
Indexed as
Identifiers
41906024What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.